Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986142 dose-ranging study in moderate to severe rheumatoid arthritis with inadequate response to methotrexate
NL-OMON43673Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-986142 in rheumatoid arthritis (RA) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: ACR20 response rate at week 12 and ACR70 response rate at week 12. Planned start Feb 2016; status: withdrawn.
02
Drugs
BMS-986142
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON43673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43673.